Shots:
- PrimeGen US has entered into a definitive business combination agreement with DT Cloud Star at an implied equity value of ~$1.5B, with closing expected in H2’26
- After closing, the combined entity is expected to operate as PrimeGen US or a successor company & will be listed on Nasdaq under a new ticker symbol
- PrimeGen will advance development of Triple Activated MSC and exosome platforms, including advancement toward a clinical trial in Acute Alcoholic Hepatitis/Acute Liver Failure following a successful FDA Pre-IND meeting
Ref: PRnewswire | Image: PrimeGen US | Press Release
Related News: GSK to Acquire RAPT Therapeutics for ~$2.2B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
